Who's the new king of the drug launch hill? Hint: It's all in the Gilead family

Move over, Sovaldi--there's a new launch king in town. And luckily for Gilead ($GILD), it's another of its own. Harvoni has officially unseated its hep C predecessor, putting up sales figures and script numbers that beat Sovaldi's at this point in its launch. Report

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…